Page last updated: 2024-10-30

labetalol and Acrania

labetalol has been researched along with Acrania in 1 studies

Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Rednic, R1
Marcovici, I1
Dragoi, R1
Pinzaru, I1
Dehelean, CA1
Tomescu, M1
Arnautu, DA1
Craina, M1
Gluhovschi, A1
Valcovici, M1
Manea, A1

Other Studies

1 other study available for labetalol and Acrania

ArticleYear
In Vitro Toxicological Profile of Labetalol-Folic Acid/Folate Co-Administration in H9c2(2-1) and HepaRG Cells.
    Medicina (Kaunas, Lithuania), 2022, Jun-10, Volume: 58, Issue:6

    Topics: Dietary Supplements; Female; Folic Acid; Humans; Hypertension; Labetalol; Neural Tube Defects; Pregn

2022